Titan Pharmaceuticals Files 8-K
| Field | Detail |
|---|---|
| Company | Titan Pharmaceuticals Inc |
| Form Type | 8-K |
| Filed Date | Aug 26, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-governance, financials
TL;DR
Titan Pharma filed an 8-K on Aug 26 for votes and financials.
AI Summary
Titan Pharmaceuticals, Inc. filed an 8-K on August 26, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing does not contain specific details on the votes or financial figures within the provided text.
Why It Matters
This filing indicates that Titan Pharmaceuticals has submitted matters for a vote and is providing financial statements, which are key events for investors to monitor company governance and financial health.
Risk Assessment
Risk Level: low — The filing is a standard procedural report and does not contain information that inherently increases risk.
Key Players & Entities
- TITAN PHARMACEUTICALS INC (company) — Registrant
- August 26, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-13341 (filing_id) — Commission File Number
- 94-3171940 (ein) — IRS Employer Identification No.
- 10 East 53 rd St. , Suite 3001 , New York , NY 10022 (address) — Address of principal executive offices
- (786) 769-7512 (phone_number) — Registrant's telephone number
FAQ
What specific matters were submitted to a vote of security holders by Titan Pharmaceuticals?
The provided text of the 8-K filing does not specify the exact matters submitted to a vote of security holders.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is August 26, 2025.
In which state was Titan Pharmaceuticals, Inc. incorporated?
Titan Pharmaceuticals, Inc. was incorporated in Delaware.
What is the Commission File Number for Titan Pharmaceuticals, Inc.?
The Commission File Number for Titan Pharmaceuticals, Inc. is 001-13341.
What is the address of Titan Pharmaceuticals, Inc.'s principal executive offices?
The address of Titan Pharmaceuticals, Inc.'s principal executive offices is 10 East 53rd St., Suite 3001, New York, NY 10022.
Filing Stats: 820 words · 3 min read · ~3 pages · Grade level 12.4 · Accepted 2025-08-26 16:05:34
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TTNP Nasdaq Capital Mark
Filing Documents
- titanpharma_8k.htm (8-K) — 40KB
- 0001829126-25-006734.txt ( ) — 202KB
- ttnp-20250826.xsd (EX-101.SCH) — 3KB
- ttnp-20250826_lab.xml (EX-101.LAB) — 33KB
- ttnp-20250826_pre.xml (EX-101.PRE) — 22KB
- titanpharma_8k_htm.xml (XML) — 4KB
07
Item 5.07. Submission of Matters to a Vote of Security Holders. On August 26, 2025, Titan Pharmaceuticals, Inc. ("Titan" or the "Company") held a special meeting of stockholders (the "Special Meeting") for the purpose of voting on Titan's proposed business combination with Black Titan Corporation, a Cayman Islands exempted company limited by shares ("Black Titan") and TalenTec Sdn. Bhd., a Malaysia private limited company, f/k/a KE Sdn. Bhd. ("TalenTec"), as fully described in the joint proxy statement/prospectus (the "Proxy Statement") filed by the Company on July 22, 2025 (the "Merger"). The Special Meeting was held pursuant to notice on August 26, 2025 at the offices of Olshan Frome Wolosky LLP located at 1325 Avenue of the Americas, 15th Floor, New York, New York 10019. As of the record date, there were 1,330,234 shares of common stock outstanding and entitled to vote at the Annual Meeting. The total number of shares of common stock voted in person or by proxy at the Special Meeting was 734,135 shares, representing approximately 55.19% of the shares of common stock outstanding and entitled to vote at the Special Meeting. At the Special Meeting, in connection with the Merger, Titan stockholders were asked to consider and vote upon the following proposals: (1) The Business Combination Proposal — to approve and adopt the Merger and Contribution and Share Exchange Agreement, dated August 19, 2024 and the transactions contemplated thereby. (2) The Nasdaq Proposal — to consider and vote upon a proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635, the issuance of Black Titan Ordinary Shares in connection with the Merger; and (3) The Adjournment Proposal — to approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary. As described below, each proposal was approved by the requisite vote of the Company's stockholders. The final voting results for each of the proposals submitted to a vote of the stockholders of
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TITAN PHARMACEUTICALS, INC. By: /s/ Chay Weei Jye Chay Weei Jye Chief Executive Officer Date: August 26, 2025 3